Wave Life Sciences
About: WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Employees: 268
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
92% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 24
73% more call options, than puts
Call options by funds: $9.23M | Put options by funds: $5.33M
60% more capital invested
Capital invested by funds: $989M [Q3] → $1.59B (+$598M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
13% more funds holding
Funds holding: 160 [Q3] → 180 (+20) [Q4]
10.08% less ownership
Funds ownership: 94.18% [Q3] → 84.1% (-10.08%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jefferies Roger Song 25% 1-year accuracy 4 / 16 met price target | 151%upside $26 | Buy Initiated | 25 Feb 2025 |
Financial journalist opinion
